Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease
- Written by PR Newswire
– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison –
DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, and...
